drugset / Trial / NCT00761592

Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm

NCT00761592

Phase 4 Completed 65 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm. Blepharospasm is characterised by excessive contraction of the muscles around the eye and can lead to repetitive blinking or sustained closure of the eyelids.

Timeline

Start
2006-07
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 40 iu